ASAI 42nd Annual Postgraduate Review Course

Friday, August 6, 2021, 6:30 PM - Sunday, August 8, 2021, 12:00 PM, Sandestin Beach Hilton, Destin, FL

Allergic disease - asthma, eczema and food allergy has increased significantly over the past couple of decades. Prevalence of food allergy in children has generally doubled.  Clinicians unfamiliarity with finer points of management is problematic.  The therapeutic landscape and best practice for pediatric food allergy has evolved rapidly over the past 5 - 10 years.  This activity will discuss the logistics and specific clinical management of early introduction of foods, IgE and non-IgE mediated reactions and infant anaphylaxis.

 

1. Demonstrate how to treat severe, uncontrolled eosinophilic asthma
2. Develop plans for navigating potential eosinophilic esophagitis patients to diagnosis
3. Utilize effective strategies for changes in coding and government regulation.
4. Improve screening strategies to identify potential eosinophilic esophagitis patients
5. Explain historic implications of consensus guidelines in the management of eosinophilic esophagitis
6. Critically evaluate the known adverse event profiles of OIT and the clinical and immunological benefits.

Children's of Alabama designates this Live Activity for a maximum of 8.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (8.00 hours), Non-Physician Attendance (8.00 hours)

Mitigation of Relevant Financial Relationships

Children's of Alabama adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

This activity will receive funds from ineligible companies.